Schools get federal funding to stock naloxone and train staff for overdose emergencies
H.R. 9251 — School Access to Naloxone Act of 2026 · Filed by Kelly Morrison (D-MN) · 3 cosponsors · Introduced Jun 10, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal law to fund grants for schools to train staff (nurses, health center workers, or designated personnel) to administer naloxone and other emergency opioid-overdose treatments on school premises. Schools must maintain accessible supplies, ensure trained staff are present during operating hours, and operate under state civil liability protections. The bill expands existing opioid-reduction grant authority to explicitly cover administration of these drugs and devices, not just prescribing.
Why we flagged it
The bill's operative mechanism is a federal grant program to equip schools with naloxone and trained personnel to administer it during overdose emergencies. This is straightforward public-health infrastructure, not a tax provision, deregulation, or private subsidy.
What the text implies
- Schools must obtain state attorney general certification that state law provides 'adequate' civil liability protection—a vague standard that may create barriers in states with weak Good Samaritan laws, effectively gatekeeping federal funding by state legal regime.
- The bill does not specify who bears the cost of naloxone supply or training; schools may face unfunded mandates if grant amounts do not cover full implementation, shifting costs to already-strained school budgets.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers of naloxone (Ampharos Pharmaceuticals, Emergent BioSolutions, Pfizer, o; medical device manufacturers producing naloxone delivery systems; school-based health center operators and contractors